Takeda: Schizophrenia trials

The registry lists 11 Schizophrenia studies with Takeda as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 5Phase 2 2Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable SchizophreniaTerminatedNCT02614586Phase 1Results posted
• A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of SchizophreniaCompletedNCT02477020Phase 2Results posted
• Roflumilast Plus Antipsychotics Proof of Mechanism Study in SchizophreniaCompletedNCT02079844Phase 1Results posted
• Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy ParticipantsCompletedNCT01879722Phase 1Results posted
• Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of SchizophreniaTerminatedNCT01760993Phase 3Results posted
• SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of SchizophreniaTerminatedNCT01760889Phase 3Results posted
• Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of SchizophreniaTerminatedNCT01738698Phase 3Results posted
• Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With SchizophreniaCompletedNCT01457339Phase 1Results posted
• Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative SymptomsCompletedNCT00922272Phase 2Results posted
• Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable SchizophreniaTerminatedNCT01900522Phase 1
• SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of SchizophreniaWithdrawnNCT01234298Phase 3